Loading...
•
Sep 30, 2021
Rigel Q3 2021 Earnings Report
Reported a net loss due to increased research and development costs related to the ongoing Phase 3 clinical trial of fostamatinib for the treatment of hospitalized patients with COVID-19, as well as increased commercial activities, including the recent sales force expansion.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $21.0 million, or $0.12 per basic and diluted share, with total revenues of $21.5 million. TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.
Net loss of $21.0 million, or $0.12 per basic and diluted share.
Total revenues were $21.5 million.
TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.
Completed enrollment of pivotal FORWARD study in wAIHA, with anticipated data readout in mid-2022.
Rigel
Rigel
Rigel Revenue by Segment
Revenue by Segment
Contract revenues from collaborations Revenue
CapyFin.com Forward Guidance
Rigel anticipates a transformative year in 2022 with pipeline candidates advancing in the clinic and sales force expansion complete.